Oncolytics Biotech Inc.
ONC.TO
TSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -27.89% | 42.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.90% | -6.80% | |||
| Operating Income | 0.90% | 6.80% | |||
| Income Before Tax | -6.46% | 18.38% | |||
| Income Tax Expenses | -- | 209.73% | |||
| Earnings from Continuing Operations | -4.05% | 15.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.05% | 15.03% | |||
| EBIT | 0.90% | 6.80% | |||
| EBITDA | 0.90% | 6.79% | |||
| EPS Basic | 1.56% | 18.99% | |||
| Normalized Basic EPS | -0.78% | 22.26% | |||
| EPS Diluted | 1.56% | 18.99% | |||
| Normalized Diluted EPS | -0.78% | 22.26% | |||
| Average Basic Shares Outstanding | 5.64% | 4.92% | |||
| Average Diluted Shares Outstanding | 5.64% | 4.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||